The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of venadaparib plus irinotecan in homologous recombination deficiency (HRD) gene mutations as 3+ line treatment in patients with metastatic gastric cancer (mGC).
 
Won Sik Lee
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Kyoung Soo Ha
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Jeongsook Bang
Employment - Idience
Stock and Other Ownership Interests - Idience
 
Minju Hong
Employment - Idience
Stock and Other Ownership Interests - Idience
 
Myongjae Lee
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Eun-Jihn Roh
Employment - Idience
Leadership - Idience
Stock and Other Ownership Interests - Idience
 
Chan-Young Ock
Employment - Lunit
Leadership - Lunit
Stock and Other Ownership Interests - Lunit; Y-Biologics
Consulting or Advisory Role - De novo biotherapeutics; GCCELL; Genome & Company; Idience; Medpacto; PIN therapeutics; Selecxine; Y-Biologics